Glenmark obtains FDA OK for generic Otezla
Otezla is used to treat plaque psoriasis for whom phototherapy or systemic therapy is appropriate;
active psoriatic arthritis; and oral ulcers associated with Behçet’s Disease.
Glenmark has received approval from the Food and Drug Administration for apremilast tablets, 10 mg, 20 mg and 30 mg, which is the generic of Amgen’s Otezla.
Otezla is used to treat: Plaque psoriasis for whom phototherapy or systemic therapy is appropriate; active psoriatic arthritis; and oral ulcers associated with Behçet’s Disease.
[Read more: Glenmark obtains FDA nod for generic Protopic]
Otezla had a market value of approximately $3.7 billion for the 12-month period ending August 2023, per IQVIA.